Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma
Yujing Xin, Xinyuan Zhang, Ning Liu, et al.
Hepatology International (2023) Vol. 17, Iss. 3, pp. 753-764
Closed Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study
Xukun Wu, Lanfang Yang, Yufeng Chen, et al.
EClinicalMedicine (2023) Vol. 67, pp. 102367-102367
Open Access | Times Cited: 23
Hepatic arterial infusion chemotherapy combined with lenvatinib and PD‐1 inhibitors versus lenvatinib and PD‐1 inhibitors for HCC refractory to TACE
Lingfeng Diao, Chendong Wang, Ran You, et al.
Journal of Gastroenterology and Hepatology (2024) Vol. 39, Iss. 4, pp. 746-753
Closed Access | Times Cited: 10
Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis
Lei Wang, Lin Li, Wei Zhou
Pharmacology & Therapeutics (2024) Vol. 257, pp. 108634-108634
Closed Access | Times Cited: 6
Pembrolizumab in combination with lenvatinib in participants with hepatocellular carcinoma (HCC) before liver transplant as neoadjuvant therapY—PLENTY pilot study
Zicheng Lv, Xuelin Xiang, Junekong Yong, et al.
International Journal of Surgery (2024) Vol. 110, Iss. 10, pp. 6647-6657
Open Access | Times Cited: 6
The current status and future of targeted-immune combination for hepatocellular carcinoma
Liyuan Hao, Shenghao Li, Fanghang Ye, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Donafenib versus sorafenib in triple therapy for unresectable hepatocellular carcinoma: a propensity score-matched multicenter analysis
Yaohong Wen, Shuyi Zhou, Yuyan Xu, et al.
World Journal of Surgical Oncology (2025) Vol. 23, Iss. 1
Open Access
The safety and efficacy of TACE combined with HAIC, PD-1 inhibitors, and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a retrospective study
Zhong-Jing Huang, Ziyi Wu, Lidong Zhang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti–PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics
Jiayi Wu, Junyi Wu, Shuqun Li, et al.
BioScience Trends (2024) Vol. 18, Iss. 1, pp. 42-48
Open Access | Times Cited: 4
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives
Yuhang Chen, Shengyuan Dai, Chien‐shan Cheng, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Transarterial Chemoembolization With or Without Systemic Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Comparative Study
Chengxiang Guo, Weibo Du, Yiwen Chen, et al.
Cancer Medicine (2025) Vol. 14, Iss. 3
Open Access
Harnessing Immunotherapy for Hepatocellular Carcinoma: Principles and Emerging Promises
Hossein Miri, Payman Rahimzadeh, Mehrdad Hashemi, et al.
Pathology - Research and Practice (2025), pp. 155928-155928
Closed Access
Safety and Survival Outcomes of Liver Resection following Triple Combination Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma
Yin Long, Jue Huang, Jianguo Liao, et al.
Cancers (2023) Vol. 15, Iss. 24, pp. 5878-5878
Open Access | Times Cited: 10
The GRAPHS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with immunotherapy
Yi Yang, Lu Li, Ying Xü, et al.
La radiologia medica (2024) Vol. 129, Iss. 2, pp. 188-201
Closed Access | Times Cited: 3
Efficacy and safety of transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors in the treatment of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Junning Liu, Wei Song, Linfeng Yang, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 15, pp. 14451-14461
Closed Access | Times Cited: 7
Immune-targeted therapy with transarterial chemo(embolization) for unresectable HCC: a systematic review and meta-analysis
Huipeng Fang, Qiao Ke, Shiji Wu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
A study on combination of non-ablative local RFA with PD-1 and angiogenesis blocking to prolong survival through improvement of immune microenvironment in advanced Hepatocellular Carcinoma
Tianlin Xiao, Sheng Hu, Shuang Dong, et al.
International Immunopharmacology (2024) Vol. 134, pp. 112144-112144
Open Access | Times Cited: 1
The efficacy and safety of Radiofrequency ablation combined with Lenvatinib plus Sintilimab in Unresectable Hepatocellular Carcinoma: a real-world study
Xi‐Shu Wang, Ximin Sun, Yongrong Lei, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Efficacy and Safety of Lenvatinib Plus Programmed Death-1 Inhibitors with or Without Transarterial Chemoembolization in the Treatment of Unresectable Hepatocellular Carcinoma
Ming Jin, Z. Gordon Jiang, Jiankang Qin, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 2309-2320
Open Access | Times Cited: 1
The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients
Zhengzheng Ji, J. Li, Shasha Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Multiparametric MRI-based Machine Learning Radiomics for Predicting Treatment Response to Transarterial Chemoembolization Combined with Targeted and Immunotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter Study
Wendi Kang, Peiyun Tang, Yingen Luo, et al.
Academic Radiology (2024)
Closed Access | Times Cited: 1
Transarterial therapy combined with bevacizumab plus immune checkpoint inhibitors as a neoadjuvant therapy for locally advanced HCC
Zhenyun Yang, Qianyu Wang, Hu Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Postoperative adjuvant immunotherapy for high-risk hepatocellular carcinoma patients
W. Zhang, Qiao Zhang, Li Tan, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 3
Combined transarterial therapy, tyrosine kinase inhibitors, and immune checkpoint inhibitors in unresectable hepatocellular carcinoma
Cheng Zhang, Yuyan Xu, Lei Cai, et al.
Research Square (Research Square) (2024)
Open Access
Research advances in immunotherapy combined with DNA damage response inhibitors for liver cancer therapy
Yang Chen, Tao Tao, Yijie Wu, et al.
Journal of Cancer Metastasis and Treatment (2024) Vol. 10, pp. 14-14
Open Access
Transarterial therapy combined with bevacizumab plus immune checkpoint inhibitors as a neoadjuvant therapy for locally advanced hepatocellular carcinoma
Zhenyun Yang, Qianyu Wang, Hu Li, et al.
Research Square (Research Square) (2024)
Open Access
Page 1 - Next Page

Scroll to top